Study provides a more accurate tool to stratify patients with HER2-positive breast cancer

By | November 21, 2022
Patients with a type of breast cancer called HER2-positive are less likely to survive if their initial treatment fails to eradicate the tumor completely and they have high levels of immune cells called tumor-infiltrating lymphocytes in the residual disease.